Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants
…, A Dohnal, C Ruf, R Gugenberger… - EMBO Molecular …, 2022 - embopress.org
The recent emergence of multiple SARS‐CoV‐2 variants has caused considerable concern
due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is…
due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is…
[HTML][HTML] Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
…, A Dohnal, C Ruf, R Gugenberger… - BioRxiv, 2021 - ncbi.nlm.nih.gov
The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern
due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is …
due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is …
Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2
…, A Steindl, R Gugenberger… - ERJ Open …, 2024 - Eur Respiratory Soc
Background APN01 is a soluble recombinant human angiotensin-converting enzyme 2 (rhACE2),
a key player in the renin–aldosterone–angiotensin system (RAAS). In clinical studies, …
a key player in the renin–aldosterone–angiotensin system (RAAS). In clinical studies, …
[PDF][PDF] APN401, a novel EPiC-based anti-cancer cell therapy Case report: Cbl-b silenced, autologous PBMCs induced stable disease in an appendix carcinoma …
R Gugenberger, A Dohnal, A Tanzmann… - … for ImmunoTherapy of …, 2022 - researchgate.net
Folie 1 Page 1 This patient was initially diagnosed with an appendix carcinoma (high grade
mucinous adenocarcinoma) and metastases in the peritoneum in May 2015. He underwent two …
mucinous adenocarcinoma) and metastases in the peritoneum in May 2015. He underwent two …
[PDF][PDF] Cbl-b silenced, autologous PBMCs as a novel anti-cancer therapy using the closed cell-processing platform EPiC–a phase 1b trial with APN401
R Gugenberger, A Dohnal, K Thell… - … for ImmunoTherapy of …, 2022 - researchgate.net
Folie 1 Page 1 Introduction Cbl-b silenced, autologous PBMCs as a novel anti-cancer therapy
using the closed cell-processing platform EPiC – a phase 1b trial with APN401 Romana …
using the closed cell-processing platform EPiC – a phase 1b trial with APN401 Romana …
A novel class of orally bioavailable small molecules induces potent and sustained tumor growth inhibition and T cell infiltration in various solid tumor mouse models
…, D Schögl, M Kuttke, A Dohnal, R Gugenberger - Cancer Research, 2024 - AACR
The introduction of targeted immunomodulating agents has transformed cancer treatment
over the last decade by demonstrating unprecedented efficacy in patients who respond. …
over the last decade by demonstrating unprecedented efficacy in patients who respond. …
Abstract LB187: Case report: APN401, a novel cancer therapy using Cbl-b silenced autologous PBMCs, induced stable disease in two patients with advanced solid …
…, M Raderer, G Prager, T Fuereder, R Gugenberger… - Cancer Research, 2023 - AACR
Immune checkpoint control is one of several mechanisms that negatively influence the immune
system and contribute to the development and progression of cancer. To enhance anti-…
system and contribute to the development and progression of cancer. To enhance anti-…
Abstract C048: Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma …
…, G Lametschwandtner, K Drobits, R Gugenberger… - Molecular Cancer …, 2019 - AACR
Introduction: The E3 ubiquitin ligase Cbl-b is an intracellular master checkpoint which negatively
regulates both adaptive and innate anti-tumor immune responses. Selective targeting of …
regulates both adaptive and innate anti-tumor immune responses. Selective targeting of …
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants (preprint)
…, A Dohnal, C Ruf, R Gugenberger… - 2021 - pesquisa.bvsalud.org
The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern
due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is …
due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is …
Evaluating inducible morphological defences in the common freshwater ciliate, Coleps hirtus
SA Wickham, E Gugenberger - Journal of plankton research, 2008 - academic.oup.com
… Eva Gugenberger … Wickham, Eva Gugenberger, Evaluating inducible morphological
defences in the common freshwater ciliate, Coleps hirtus, Journal of Plankton Research …
defences in the common freshwater ciliate, Coleps hirtus, Journal of Plankton Research …